Third-line dovitinib in metastatic renal cell carcinoma
Mené sur 570 patients atteints d'un carcinome rénal métastatique, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du dovetinib et du sorafenib en traitement de troisième ligne
The Lancet Oncology, sous presse, 2014, commentaire
Résumé en anglais
The identification of VEGF and mTOR as important drivers of metastatic renal cell carcinoma 1 led to the development of agents targeting these pathways. Today, several agents have been approved for first-line (sunitinib, bevacizumab plus interferon alfa, pazopanib, and temsirolimus) or second-line treatment (sorafenib, everolimus, pazopanib, and axitinib) of metastatic renal cell carcinoma, 2 mainly because of longer progression-free survival (PFS) with these agents than with the previous standard ...
